Known risk factors include among others success in preclinical and clinical trials especially if based on a small patient sample does not ensure that later clinical trials will be successful the data presented in this release may not be consistent with the final data set and analysis thereof or result in a safe or effective treatment benefit different methodologies assumptions and applications we utilize to assess particular safety or efficacy parameters may yield different statistical results and even if we believe the data collected from clinical trials of our product candidates are positive these data may not be sufficient to support approval by the FDA or foreign regulatory authorities if the actual number of patients suffering from DMD is smaller than estimated our revenue and ability to achieve profitability may be adversely affected we may not be able to execute on our business plans and goals including meeting our expected or planned regulatory milestones and timelines clinical development plans and bringing our product candidates to market due to a variety of reasons some of which may be outside of our control including possible limitations of company financial and other resources manufacturing limitations that may not be anticipated or resolved for in a timely manner regulatory court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the COVID19 pandemic and even if Sareptas programs result in new commercialized products Sarepta may not achieve the expected revenues from the sale of such products and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10K for the year ended December 31 2020 as well as other Securities and Exchange Commission SEC filings made by the Company which you are encouraged to review